HRP20130876T1 - Sredstvo za prevenciju ili lijeäśenje glaukoma - Google Patents

Sredstvo za prevenciju ili lijeäśenje glaukoma Download PDF

Info

Publication number
HRP20130876T1
HRP20130876T1 HRP20130876TT HRP20130876T HRP20130876T1 HR P20130876 T1 HRP20130876 T1 HR P20130876T1 HR P20130876T T HRP20130876T T HR P20130876TT HR P20130876 T HRP20130876 T HR P20130876T HR P20130876 T1 HRP20130876 T1 HR P20130876T1
Authority
HR
Croatia
Prior art keywords
preventive
agent against
carbonic anhydrase
rho kinase
curative agent
Prior art date
Application number
HRP20130876TT
Other languages
English (en)
Inventor
Ken Mizuno
Jiro Matsumoto
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Publication of HRP20130876T1 publication Critical patent/HRP20130876T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

1. Preventivno ili ljekovito sredstvo protiv glaukoma, naznačeno time, da sadržava inhibitor Rho kinazu i inhibitor ugljičnu anhidrazu u kombinaciji.
2. Preventivno ili ljekovito sredstvo protiv glaukoma prema zahtjevu 1, naznačeno time, da je inhibitor Rho kinaza (S)-(-)-1-(4-fluoro-5-isokinolinsulfonil)-2-metil-1,4-homopiperazin ili njegova sol, ili solvat.
3. Preventivno ili ljekovito sredstvo protiv glaukoma u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je inhibitor ugljična anhidraza brinzolamid.
4. Preventivno ili ljekovito sredstvo protiv glaukoma prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da je to kombinacija lijekova.
5. Preventivno ili ljekovito sredstvo protiv glaukoma prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da je to komplet koji sadržava lijek sa inhibitorom Rho kinaza i lijek sa inhibitorom ugljična anhidraza.
6. Preventivno ili ljekovito sredstvo protiv povišenog očnog tlaka, naznačeno time, da sadržava inhibitor Rho kinazu i inhibitor ugljičnu anhidrazu u kombinaciji.
7. Preventivno ili ljekovito sredstvo protiv povišenog očnog tlaka prema zahtjevu 6, naznačeno time, da je inhibitor Rho kinaza (S)-(-)-1-(4-fluoro-5-izokinolinsulfonil)-2-metil- 1,4-homopiperazin ili njegova sol, ili solvat.
8. Preventivno ili ljekovito sredstvo protiv povišenog očnog tlaka u skladu s patentnim zahtjevom 6 ili 7, naznačeno time, da je inhibitor ugljična anhidraza brinzolamid.
9. Preventivno ili ljekovito sredstvo protiv povišenog očnog tlaka prema bilo kojem od zahtjeva 6 do 8, naznačeno time, da je to kombinacija lijekova.
10. Preventivno ili ljekovito sredstvo protiv povišenog očnog tlaka prema bilo kojem od zahtjeva 6 do 8, naznačeno time, da je to komplet koji sadržava lijek sa inhibitorom Rho kinaza i lijek sa inhibitorom ugljična anhidraza.
11. Upotreba inhibitora Rho kinaza i inhibitora ugljična anhidraza u kombinaciji, naznačena time, da je upotreba namijenjena proizvodnji preventivnog ili ljekovitog sredstva protiv glaukoma.
12. Upotreba inhibitora Rho kinaza i inhibitora ugljična anhidraza u kombinaciji, naznačena time, da je upotreba namijenjena proizvodnji preventivnog ili ljekovitog sredstva protiv povišenog očnog tlaka.
HRP20130876TT 2005-07-12 2013-09-18 Sredstvo za prevenciju ili lijeäśenje glaukoma HRP20130876T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005203352 2005-07-12
PCT/JP2006/313740 WO2007007737A1 (ja) 2005-07-12 2006-07-11 緑内障を予防又は治療する薬剤

Publications (1)

Publication Number Publication Date
HRP20130876T1 true HRP20130876T1 (hr) 2013-10-25

Family

ID=37637126

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130876TT HRP20130876T1 (hr) 2005-07-12 2013-09-18 Sredstvo za prevenciju ili lijeäśenje glaukoma

Country Status (11)

Country Link
US (1) US8193193B2 (hr)
EP (1) EP1905452B1 (hr)
JP (1) JP4972552B2 (hr)
KR (1) KR101333990B1 (hr)
CN (1) CN101198355B (hr)
DK (1) DK1905452T3 (hr)
ES (1) ES2416334T3 (hr)
HR (1) HRP20130876T1 (hr)
PL (1) PL1905452T3 (hr)
PT (1) PT1905452E (hr)
WO (1) WO2007007737A1 (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5220414B2 (ja) 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
JP5234825B2 (ja) 2007-07-02 2013-07-10 旭化成ファーマ株式会社 スルホンアミド化合物及びその結晶
TW202239413A (zh) * 2011-02-04 2022-10-16 日商興和股份有限公司 眼科用製劑
JP2013129604A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する徐放性フィルム製剤
JP2013129605A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する安定なフィルム製剤
JP2015229671A (ja) * 2014-06-06 2015-12-21 株式会社デ・ウエスタン・セラピテクス研究所 網膜色素上皮細胞保護剤
EP3199155B1 (en) * 2014-09-24 2021-06-16 Kowa Company, Ltd. Corneal thickness modulating agent
DK3199161T3 (da) * 2014-09-25 2022-01-03 Kowa Co Farmaceutisk præparat
MY177032A (en) * 2014-09-25 2020-09-02 Kowa Co Aqueous composition
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
TWI699207B (zh) * 2015-08-31 2020-07-21 日商興和股份有限公司 拉巴斯吉之用於製造眼壓下降增強劑之用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) * 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US3885047A (en) * 1972-06-16 1975-05-20 Mead Johnson & Co Ocular hypotensive process employing dextrorotatory phenethanolamines
US4483864A (en) * 1983-02-04 1984-11-20 University Of Iowa Research Foundation Non-classical topical treatment for glaucoma
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
ES2042625T5 (es) 1987-04-03 2000-07-16 Univ Columbia Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
JP4316794B2 (ja) 1997-10-22 2009-08-19 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリン誘導体及び医薬
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
EP1459743B9 (en) 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
KR100818061B1 (ko) 2000-03-16 2008-04-01 미쯔비시 웰 파마 가부시키가이샤 아미드 화합물 및 그의 용도
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
US7442686B2 (en) * 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
IL162475A0 (en) * 2001-12-12 2005-11-20 Pharmacia Corp Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
WO2003059913A1 (en) 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7294646B2 (en) * 2002-06-17 2007-11-13 Merck & Co. Inc. Maxi-k channel blockers, methods of use and process for making the same
US20050245509A1 (en) * 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
JP4482726B2 (ja) 2002-08-29 2010-06-16 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CA2506464C (en) * 2002-11-18 2012-07-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
JP2004250410A (ja) 2003-02-21 2004-09-09 Mitsubishi Pharma Corp 腎臓における虚血−再灌流障害の治療剤
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
US20070004771A1 (en) 2003-10-06 2007-01-04 Glaxo Group Limited Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors
JP4764823B2 (ja) 2003-10-06 2011-09-07 グラクソ グループ リミテッド キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
ES2426288T3 (es) 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
WO2005099691A1 (en) * 2004-03-31 2005-10-27 Pharmacia & Upjohn Company Llc Composition for treating elevated intraocular pressure
CN101198325A (zh) * 2004-10-13 2008-06-11 默克公司 用于治疗高眼压的眼用组合物
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma

Also Published As

Publication number Publication date
KR101333990B1 (ko) 2013-11-27
EP1905452A1 (en) 2008-04-02
DK1905452T3 (da) 2013-07-01
US8193193B2 (en) 2012-06-05
JPWO2007007737A1 (ja) 2009-01-29
EP1905452B1 (en) 2013-06-19
WO2007007737A1 (ja) 2007-01-18
US20090118299A1 (en) 2009-05-07
EP1905452A4 (en) 2012-02-15
JP4972552B2 (ja) 2012-07-11
CN101198355B (zh) 2010-11-10
PL1905452T3 (pl) 2013-11-29
KR20080027827A (ko) 2008-03-28
CN101198355A (zh) 2008-06-11
ES2416334T3 (es) 2013-07-31
PT1905452E (pt) 2013-07-16

Similar Documents

Publication Publication Date Title
HRP20130876T1 (hr) Sredstvo za prevenciju ili lijeäśenje glaukoma
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
RS54707B1 (en) TREATMENT OF CROWN LAKVINIMOD DISEASE
HRP20180942T1 (hr) Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima
IL192053A (en) 2-Admentiluria derivatives as selective inhibitors of 1hsd-β11 and their use in drug preparation
IL216928A (en) A crystalline form of 2- {4- [n- (5,6-diphenylpyrazine-2-ram) - n-isopropylamino] butoxy} - n- (methylsulfonyl) acetamide, its pharmaceutical composition and its use in the preparation of a drug
IL190284A (en) Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
TW200806300A (en) New therapeutic combinations for the treatment of depression
WO2009121872A3 (en) Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
BRPI0514296A (pt) combinação de um inibidor seletivo da recaptação de noradrenalina e um inibidor da pdev
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
AR050696A1 (es) Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
EA201170101A1 (ru) Фармацевтические композиции роувастатина кальция
EP4257189A3 (en) Pharmaceutical combination comprising a biguanid and an acetylcholinesterase inhibitor for use in age-related and/or degenerative diseases
IL199214A (en) A product containing a combination of pamirolast and statin, pharmaceuticals and kits containing it and their uses in the treatment of inflammatory conditions
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
TW200738635A (en) New salt
CL2007003110A1 (es) Compuestos derivados de ciclohexilamida, moduladores de los receptores de serotonina 5-ht2a y dopamina d3; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos cognitivos, adiccion a las drogas, depresi
TW200637824A (en) Benzamide derivatives
GR1006148B (el) Αναβραζοντα δισκια και αναβραζοντα κοκκια που περιεχουν τρυγικη καρνιτινη
CL2007003281A1 (es) Compuesto 1-(4-metilfenil)dihidro-1h-pirrolo[1,2-a]imidazol-2,5-(3h,6h)-diona; composicion farmaceutica; y uso para el tratamiento terapeutico o preventivo de la neurotoxicidad periferica inducida por quimioterapeuticos.
TW200626149A (en) Tricycles, their manufacture and use as pharmaceutical agents